Neoadjuvant FOLFOXIRI plus bevacizumab without radiotherapy for high-risk rectal cancer: multicentre phase II trial
In this phase II trial, although recruitment was suboptimal, neoadjuvant FOLFOXIRI plus bevacizumab achieved good local control without radiotherapy in patients with high-risk LARC. Although the pCR rate was modest compared with radiotherapy-based regimens, this chemotherapy-only approach may represent a reasonable option for select patients who are not suitable candidates for pelvic radiotherapy. Registration number: UMIN000037367 (https://www.umin.ac.jp/english/).
Authors
- Yoshihiro Kakeji (ORCID: https://orcid.org/0000-0002-2727-0241)
- Takahiro Tsuboyama (ORCID: https://orcid.org/0000-0002-7243-1454)
- Yoshiaki Nagatani (ORCID: https://orcid.org/0009-0000-6153-6456)
- Yohei Funakoshi
- Takeru Matsuda (ORCID: https://orcid.org/0000-0002-1572-5085)
- Tomohiro Tanaka (ORCID: https://orcid.org/0000-0001-9512-4839)
- Kunihiko Kaneda
- Naomi Kiyota
- Hiroshi Hasegawa
- Yasuhiko Mii
- Kimihiro Yamashita
Institutions
- Tokyo-Kita Medical Center (JP)
- Kagawa Prefectural Central Hospital (JP)
- Kobe University (JP)
Publication Details
- Journal
- BJS Open
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1093/bjsopen/zraf163
- Primary Topic
- Colorectal Cancer Surgical Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00